InvestorsHub Logo
Followers 52
Posts 2232
Boards Moderated 0
Alias Born 07/06/2011

Re: KMBJN post# 10795

Friday, 12/02/2016 11:06:44 AM

Friday, December 02, 2016 11:06:44 AM

Post# of 16885
Neuroderm is developing an apomorphine dopamine agonist continuous delivery system that may be competing with our ropinirole dopamine agonist implant.

http://finance.yahoo.com/news/neuroderm-announces-top-line-results-120000884.html

Both offer continuous delivery of a dopamine agonist. Right now Neuroderm only has subcutaneous pump type delivery of their levodopa formulation and now their apomorphine drug. Soon they will have a disposable patch-pump for administration, better than the belt worn pump, IMO.

Previous dopamine agonist daily skin patch Neupro (rotigotine) didn't go well due to manufacturing issues, recalled in 2008, and now back again doing pretty well for UCB - with 216M Euros in sales in 2015.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TTNP News